Top Biomed Stock Signal: OCGN
Report Date: 11-27-2023
Symbol: OCGN - Ocugen, Inc.
Sector:
Industry:
Top Biomed Stock Signal: OCGN
Ocugen, Inc. (OCGN)
5 Great Valley Pkwy Ste 160
Malvern, PENNSYLVANIA 19355
Phone: 14843284698
Website: http://www.ocugen.com
CEO: Dr. Shankar Musunuri
NASDAQ, Nasdaq Global Select
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 49 full-time employees. The firm offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The firm is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The firm is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).